Oral ibandronate reduces activation frequency to healthy premenopausal levels in women with postmenopausal osteoporosis

被引：0
|
作者：
不详
机构：
来源：
CALCIFIED TISSUE INTERNATIONAL | 2006年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S155 / S156
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis (PMO)
    Cooper, C
    Hawker, G
    Emkey, R
    McDonald, R
    Schimmer, R
    Mahoney, P
    Wilson, K
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S206 - S206
  • [22] Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety
    Epstein, S
    Delmas, PD
    Emkey, R
    Wilson, KM
    Hiltbrunner, V
    Schimmer, RC
    MATURITAS, 2006, 54 (01) : 1 - 10
  • [23] Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis
    Lewiecki, E. Michael
    Keaveny, Tony M.
    Kopperdahl, David L.
    Genant, Harry K.
    Engelke, Klaus
    Fuerst, Thomas
    Kivitz, Alan
    Davies, Richard Y.
    Fitzpatrick, Lorraine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01): : 171 - 180
  • [24] Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study
    Recker R.R.
    Weinstein R.S.
    Chesnut III C.H.
    Schimmer R.C.
    Mahoney P.
    Hughes C.
    Bonvoisin B.
    Meunier P.J.
    Osteoporosis International, 2004, 15 (3) : 231 - 237
  • [25] Oral monthly ibandronate in postmenopausal osteoporosis: Rationale and design of the mobile study
    Cooper, C
    Delmas, PD
    Coutant, K
    Bonvoisin, B
    Recker, RR
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S55 - S55
  • [26] Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis
    Reginster, JY
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (13) : 2301 - 2313
  • [27] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
    Hadji, P.
    Benhamou, C. -L.
    Devas, V.
    Masanauskaite, D.
    Barrett-Connor, E.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [28] Ibandronate: The evolution of a once-a-month oral therapy for postmenopausal osteoporosis
    Dempster, DW
    Bolognese, MA
    JOURNAL OF CLINICAL DENSITOMETRY, 2006, 9 (01) : 58 - 65
  • [29] Both oral and intravenous ibandronate effectively prevent postmenopausal bone loss in women without osteoporosis.
    Adachi, JD
    Christiansen, C
    Stakkestad, JA
    McClung, M
    Burdeska, A
    Mahoney, P
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S372 - S372
  • [30] Efficacy of oral ibandronate in postmenopausal osteoporosis: Incidence of vertebral fractures by subgroup
    Ettinger, M
    Emkey, R
    Schimmer, R
    Mahoney, P
    Kilbride, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S206 - S207
12345